Compare UTHR & GPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | GPN |
|---|---|---|
| Founded | 1996 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 21.8B |
| IPO Year | 1999 | 2000 |
| Metric | UTHR | GPN |
|---|---|---|
| Price | $586.57 | $72.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $567.57 | $92.50 |
| AVG Volume (30 Days) | 554.5K | ★ 2.7M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.41% |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 27.86 | 5.78 |
| Revenue | $1,483,300,000.00 | ★ $3,975,163,000.00 |
| Revenue This Year | $7.08 | $63.81 |
| Revenue Next Year | $14.32 | $6.27 |
| P/E Ratio | $20.81 | ★ $12.25 |
| Revenue Growth | 2.38 | ★ 17.92 |
| 52 Week Low | $272.18 | $62.45 |
| 52 Week High | $607.89 | $90.64 |
| Indicator | UTHR | GPN |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 58.34 |
| Support Level | $464.92 | $71.24 |
| Resistance Level | $607.89 | $73.21 |
| Average True Range (ATR) | 17.12 | 2.54 |
| MACD | -0.23 | 0.97 |
| Stochastic Oscillator | 63.42 | 92.66 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.